The Use of Remimazolam Versus Dexmedetomidine for Patients Receiving Drug-Induced Sleep Endoscopy

The Use of Remimazolam Versus Dexmedetomidine for Patients Receiving Drug-Induced Sleep Endoscopy

This study seeks to compare the clinical efficacy and safety of the novel sedative Remimazolam with Dexmedetomidine in Drug-Induced Sleep Endoscopy (DISE), evaluating their performance in sedation depth stability, incidence of adverse events, and postoperative recovery time, thereby providing evidence-based guidance for sedative selection in OSA patients. Additionally, it aims to develop a model for predicting upper airway obstruction sites by analyzing Polysomnography (PSG) data with artificial intelligence, enhancing diagnostic accuracy and treatment decision-making efficiency for Obstructive Sleep Apnea (OSA) to optimize clinical management.

Inclusion Criteria:

• Patients age > 18 years old
• American Society of Ansthesiologists functional class < III
• Schedule to receive DISE exam for evaluation of OSAS

Exclusion Criteria:

• Patient refusal
• Allergic to experimental medication
• History of central nervous system diseases
• History of psychiatric diseases
• Pregnancy
• Severe, uncontrolled systemic diseases